Achieving an early myeloma response in patients with kidney impairment.
Adv Chronic Kidney Dis
; 19(5): 303-11, 2012 Sep.
Article
in En
| MEDLINE
| ID: mdl-22920641
ABSTRACT
There is increasing evidence, particularly in severe acute kidney injury, that treatment of multiple myeloma with regimens that include dexamethasone in combination with novel chemotherapy agents are associated with an early disease response in most patients. However, the evidence to guide the optimal chemotherapy regimen in patients with kidney impairment is limited, and treatment choices are complicated by the effect of kidney function on drug dosing. Here, we summarize the current status of this field, with a particular focus on chemotherapy regimens that are based on dexamethasone and novel agents and an outline of those areas in which further work is needed to improve the evidence base.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Acute Kidney Injury
/
Multiple Myeloma
Type of study:
Etiology_studies
Limits:
Humans
Language:
En
Journal:
Adv Chronic Kidney Dis
Journal subject:
NEFROLOGIA
Year:
2012
Document type:
Article
Affiliation country:
United kingdom